Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02288429 · ClinicalTrials.gov registry record
Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium
A clinical trial of Colistin, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 16
- Enrollment target
- 1
- Study location
NCT02288429: Completed study of Colistin, sponsored by University of Colorado, Denver.
NCT02288429 is a study of Colistin that has completed, run by University of Colorado, Denver. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02288429, a study of Colistin, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Colistin is a polymixin antibiotic used in the treatment of multidrug-resistant gram-negative infections. Given the limited use of colistin and previous challenges with laboratory assays to determine plasma concentrations, there is a lack of knowledge of the pharmacokinetic profile of colistin. The purpose of the investigators observational prospective pharmacokinetic cohort study is to examine the steady-state pharmacokinetic and pharmacodynamic properties of intravenous colistimethate sodium in cystic fibrosis and critically ill patients.
Primary Outcome
Steady-state plasma concentrations will be obtained after at least 2 days of therapy. Blood draws (5 ml) will be taken just before the start of the colistimethate sodium infusion and at 30, 60, 120, 240, and 360 minutes after the IV infusion.
Conditions Studied
Interventions
- DRUG colistimethate sodium
Study Locations (1)
California
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-09 |
| Est. Completion | 2019-06 |
What the finished NCT02288429 record still lists
NCT02288429 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 1 condition, with Colistin appearing as the primary indexed condition, and to 1 intervention - of which colistimethate sodium is the first listed.
NCT02288429 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02288429 about?
NCT02288429 is a clinical study titled "Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium". Colistin is a polymixin antibiotic used in the treatment of multidrug-resistant gram-negative infections. Given the limited use of colistin and previous challenges with laboratory assays to determine plasma concentrations, there is a lack of knowledge of the pharmacokinetic profile of colistin. The ...
What is the current status of trial NCT02288429?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2013-09. Estimated completion is 2019-06.
What conditions does trial NCT02288429 study?
This clinical trial studies the following conditions: Colistin.
What interventions are being tested in trial NCT02288429?
The interventions under investigation include: colistimethate sodium (DRUG).
Who is sponsoring clinical trial NCT02288429?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02288429 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia